-
Mashup Score: 109CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study - 6 month(s) ago
This trial identifies CD22 as an immunotherapeutic target in large B-cell lymphoma and demonstrates the durable clinical activity of CAR22 in patients with disease progression after CAR19 therapy. Although these findings are promising, it is essential to recognise that this is a phase 1 dose-finding study. Further investigations are warranted to establish the long-term efficacy and to delineate the patient subgroups that will derive the most benefit from this therapeutic approach.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 109CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study - 6 month(s) ago
This trial identifies CD22 as an immunotherapeutic target in large B-cell lymphoma and demonstrates the durable clinical activity of CAR22 in patients with disease progression after CAR19 therapy. Although these findings are promising, it is essential to recognise that this is a phase 1 dose-finding study. Further investigations are warranted to establish the long-term efficacy and to delineate the patient subgroups that will derive the most benefit from this therapeutic approach.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Fresh off the press, exciting results from Frank et al @StanfordMed CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study https://t.co/q6u0mm6SGo Looking forward to the multicenter phase 2… https://t.co/2z3lzcdwzI
-
-
Mashup Score: 0Paul Auster, American author of The New York Trilogy, dies aged 77 - 9 month(s) ago
The writer of The New York Trilogy, Leviathan and 4 3 2 1 – known for his stylised postmodernist fiction – has died from complications of lung cancer
Source: www.theguardian.comCategories: General Medicine News, Hem/OncsTweet-
😢 Any favorite Auster book recommendations? https://t.co/sUnMtplHeH
-
-
Mashup Score: 39Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity - 9 month(s) ago
Bone Marrow Transplantation – Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
🎉 New publication in @BMTjournal from my group @fredhutch in collaboration with @RShouval @MSKCancerCenter! https://t.co/3yGjv8W3Nz Ordinal scales have immense value but can be very labor-intensive when manual grading is needed. To address this issue, we repurposed the… https://t.co/wpTKF1Jktf https://t.co/yqsbDhMrRo
-
-
Mashup Score: 39Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity - 9 month(s) ago
Bone Marrow Transplantation – Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
🎉 New publication in @BMTjournal from my group @fredhutch in collaboration with @RShouval @MSKCancerCenter! https://t.co/3yGjv8W3Nz Ordinal scales have immense value but can be very labor-intensive when manual grading is needed. To address this issue, we repurposed the… https://t.co/wpTKF1Jktf https://t.co/yqsbDhMrRo
-
-
Mashup Score: 101
Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had no standard of care In TRANSCEND CLL 004, the first pivotal multicenter trial to evaluate a CAR T cell therapy in patients with relapsed or refractory CLL or SLL, 20% of patients treated with Breyanzi achieved a complete response (CR) with median duration of CR not reached, along with an established safety profile Breyanzi is now FDA approved for relapsed or refractory large B-cell lymphoma and CLL or SLL, bringing this differentiated CD19-directed CAR T cell therapy to more patients Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet-
The @US_FDA approves @bmsnews lisocabtagene maraleucel for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Kudos to all investigators and sites involved! https://t.co/wqQ6N6Sluc @mshadman
-
-
Mashup Score: 100
Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had no standard of care In TRANSCEND CLL 004, the first pivotal multicenter trial to evaluate a CAR T cell therapy in patients with relapsed or refractory CLL or SLL, 20% of patients treated with Breyanzi achieved a complete response (CR) with median duration of CR not reached, along with an established safety profile Breyanzi is now FDA approved for relapsed or refractory large B-cell lymphoma and CLL or SLL, bringing this differentiated CD19-directed CAR T cell therapy to more patients Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet-
The @US_FDA approves @bmsnews lisocabtagene maraleucel for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Kudos to all investigators and sites involved! https://t.co/wqQ6N6Sluc @mshadman
-
-
Mashup Score: 6Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians - Bone Marrow Transplantation - 11 month(s) ago
We are pleased to add this typescript to the Bone Marrow Transplantation Statistics Series. We realize the term cubic splines may be a bit off-putting to some readers, but stay with us and don’t get lost in polynomial equations. What the authors describe is important conceptually and in practice. Have you ever tried to buy a new pair of hiking boots? Getting the correct fit is critical; shoes…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Restricted cubic splines to the rescue! https://t.co/IFcgSMSeVt https://t.co/fAtzfte6g0
-
-
Mashup Score: 48LinkedIn - 11 month(s) ago
This link will take you to a page that’s not on LinkedIn
Source: lnkd.inCategories: General Medicine News, Hem/OncsTweet-
Proud of Dr. @NGazeau14 who received today the 2023 Robert Korngold Award for the Best Clinical Science article published in @ASTCT_Journal Link to the publication: https://t.co/RBO3HcBvux Congrats again Nicolas and thanks to all collaborators! #Tandem24 @ASTCT Photo credit:… https://t.co/flIV2ZcPfJ https://t.co/5xoQEZGq2Z
-
-
Mashup Score: 29FDA wants classwide boxed warning on all commercial CAR-T therapies amid secondary cancer safety probe - 12 month(s) ago
As many have feared, the FDA’s investigation into secondary T-cell cancers following treatment with existing CAR-T therapies is poised to lead to a classwide black box warning. | As many have feared, the FDA’s investigation into secondary T-cell malignancies following treatment with existing CAR-T therapies is poised to lead to a classwide black box warning.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet-
FDA wants classwide boxed warning on all commercial CAR-T therapies amid secondary cancer safety probe https://t.co/3O8QJqZlPP
-
Fresh off the press, exciting results from Frank et al @StanfordMed CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study https://t.co/q6u0mm6SGo Looking forward to the multicenter phase 2… https://t.co/2z3lzcdwzI